{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:58:05Z","timestamp":1791068285666,"version":"4.1.0"},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"2a","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>OBJECTIVE: The aim of our study was to evaluate the effects of low doses of clozapine in flexible regime in comparison with haloperidol and chlorpromazine in long term. METHOD: The naturalistic study was prospective, active-controlled with 325 adult outpatients of both genders (140 females), with mean year age of 34.8 (range 21-57), suffering from chronic schizophrenia. The first onset of illness was at the mean of 27.9 years (range 17-38), and subjects had the mean year age of 4.1\u00b10.5 previous relapses. The patients were allocated to receive haloperidol (105 subjects, dose range 2-15 mg), chlorpromazine (n=105, 100-400 mg) or clozapine (n=115, 75-600 mg). The scores of psychometric instruments (GWB, PANSS, CGI) were regularly assessed during 5 year period. RESULTS: The sixty-six responders were included in per-protocol analysis: 12, 10 and 16 with positive and 7, 6 and 15 with negative schizophrenic syndrome in haloperidol, chlorpromazine and clozapine group, respectively. The statistically significant differences in all psychometric scores was found, for both schizophrenic syndromes, favoring clozapine. The distribution of eighteen different types of adverse events, which we noted, were significantly different among treatment groups ( \u03c72=315.7, df=34, p&lt;0.001). Clozapine was safer and had fewer adverse effects (average of 0.9 adverse events per patient) than haloperidol (2.7) and chlorpromazine (3.2). CONCLUSIONS: Clozapine, in low doses of flexible regime, in long term (five years) showed better effectiveness in chronic schizophrenics with positive and negative symptoms than typical antipsychotics.<\/jats:p>","DOI":"10.1590\/s0004-282x2009000200005","type":"journal-article","created":{"date-parts":[[2009,6,19]],"date-time":"2009-06-19T05:59:06Z","timestamp":1245391146000},"page":"195-202","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period"],"prefix":"10.1590","volume":"67","author":[{"given":"Dragan B.","family":"Ravanic","sequence":"first","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavica M. Djukic","family":"Dejanovic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Janjic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana D.","family":"Jovic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan R.","family":"Milovanovic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Jakovljevic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Pantovic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Ravanic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Pantovic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihailo M.","family":"Pantovic","sequence":"additional","affiliation":[{"name":"Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/schbul\/14.4.645","article-title":"The heterogeneity of the long-term course of schizophrenia","volume":"14","author":"Carpenter WT","year":"1988","journal-title":"Schizophr Bull","ISSN":"https:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1192\/S0007125000071919","article-title":"Positive and negative schizophrenic symptoms and the role of dopamine","volume":"137","author":"Crow TJ","year":"1980","journal-title":"Br Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/schbul\/14.4.501","article-title":"European long-term follow-up studies in schizophrenia","volume":"14","author":"Angst J","year":"1988","journal-title":"Shizophr Bull"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00004714-198612000-00002","article-title":"The effects of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia","volume":"6","author":"Meltzer HY","year":"1986","journal-title":"J Clin Psychopharmacology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1600-0447.1988.tb05164.x","article-title":"The effects of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years","volume":"77","author":"Lindstrom IH","year":"1987","journal-title":"Acta Psychiatr Scand","ISSN":"https:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0006-3223(90)90502-S","article-title":"Mutability and relationships between positive and negative symptoms during neuroleptic treatment in schizophrenia","volume":"27","author":"Tandon R","year":"1990","journal-title":"Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00004850-200505000-00006","article-title":"Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment","volume":"20","author":"Ahn YM","year":"2005","journal-title":"Int Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0268-1315","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1007\/BF00442572","article-title":"Tolerability of long term clozapine treatment","volume":"99","author":"Schmauss M","year":"1989","journal-title":"Psychopharmacology (Berl)","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref9","first-page":"385","article-title":"Long-term clinical experience with clozapin","volume":"23","author":"Gelly F","year":"1997","journal-title":"Encephale","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7006","issn-type":"print"},{"key":"ref10","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn RM","year":"2007","journal-title":"J Psychiatry Neurosci","ISSN":"https:\/\/id.crossref.org\/issn\/1180-4882","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.v64n0416","article-title":"Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study","volume":"64","author":"Ciapparelli A","year":"2003","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0278-5846(94)90010-8","article-title":"The side-effects of clozapine: a four-year follow-up study","volume":"18","author":"Marinkovic D","year":"1994","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0278-5846","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay SR","year":"1987","journal-title":"Shizophr Bull"},{"key":"ref14","series-title":"ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW Publ No ADM 76-338)","first-page":"218","author":"Guy W","year":"1976"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1034\/j.1600-0447.2000.102004303.x","article-title":"The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale","volume":"102","author":"Norman RM","year":"2000","journal-title":"Acta Psychiatr Scand","ISSN":"https:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"key":"ref16","series-title":"Practical statistics for medical research","author":"Altman DG","year":"1991"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck K","year":"1999","journal-title":"Am J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref18","first-page":"CD000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","volume":"2","author":"Wahlbeck K","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4088\/JCP.v64n0703","article-title":"The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study","volume":"64","author":"Spivak B","year":"2003","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/bjp.183.2.161","article-title":"Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination","volume":"183","author":"Moncrieff J","year":"2003","journal-title":"Br J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1250","issn-type":"print"},{"key":"ref21","first-page":"384","article-title":"A critical review of the pragmatic clinical trial","volume":"121","author":"Vallve C","year":"2003","journal-title":"Med Clin (Barc)","ISSN":"https:\/\/id.crossref.org\/issn\/0025-7753","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1046\/j.1440-1614.2002.01091.x","article-title":"A five year follow-up study of the use of clozapine in community practice","volume":"36","author":"Drew LR","year":"2002","journal-title":"Aust N Z J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0004-8674","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/BF02245620","article-title":"Clozapine versus typical antipsychotics: A retro- and prospective study of extrapyramidal side effects","volume":"124","author":"Peacock L","year":"1996","journal-title":"Psychopharmacology (Berl)","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00002826-200009000-00007","article-title":"Myotoxicity and neurotoxicity during clozapine treatment","volume":"23","author":"Reznik I","year":"2000","journal-title":"Clin Neuropharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0362-5664","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00019053-199711010-00005","article-title":"Measuring quality of life in patients with schizophrenia","volume":"11","author":"Awad AG","year":"1997","journal-title":"Pharmacoeconomics","ISSN":"https:\/\/id.crossref.org\/issn\/1170-7690","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","article-title":"\u03b12C-Adrenoceptor blockade by clozapine and other antipsychotic drugs","volume":"462","author":"Kalkman HO","year":"2003","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.npp.1300591","article-title":"The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist","volume":"30","author":"Shilliam CS","year":"2005","journal-title":"Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0893-133X","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn RS","year":"2008","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman JA","year":"2005","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis JM","year":"2004","journal-title":"J Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eurpsy.2005.09.009","article-title":"Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia","volume":"21","author":"Martin JL","year":"2006","journal-title":"Eur Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0278-5846(98)00087-6","article-title":"Clinical outcome to clozapine treatment in chronic psychiatric inpatients","volume":"23","author":"Advokat CD","year":"1999","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0278-5846","issn-type":"print"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v67n2a\/v67n2aa05.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T18:38:34Z","timestamp":1685039914000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2009000200005&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":32,"journal-issue":{"issue":"2a","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0004-282X2009000200005"],"URL":"https:\/\/doi.org\/10.1590\/s0004-282x2009000200005","relation":{},"ISSN":["0004-282X"],"issn-type":[{"value":"0004-282X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}